Register
Login:
Share:
Email Facebook Twitter


London South East Natural Resources Briefing webcast: #Emmerson #Alba #Condor Gold #Gold analysis
Angus Energy in talks to buy 'transformational' gas asset in North England


Nuformix Share Chat (NFX)



Share Price: 7.90Bid: 7.80Ask: 8.00Change: 0.05 (+0.64%)Riser - Nuformix
Spread: 0.20Spread as %: 2.56%Open: 8.15High: 8.15Low: 7.90Yesterday’s Close: 7.85


Share Discussion for Nuformix




View all NFX Messages

Please login or register to post a message on Share Chat.

Posts per page:

Aim4Utopia
Posts: 5,642
Premium Chat Member
Opinion:No Opinion
Price:3.18
RE: Look at the wording
22 Apr '19
Scary, I’m not that interested in the longer scale payments on the R and D side of the canaboid deal. Yes there will be payment af around £1 mil this year and further larger payments the following years.
What I am interested in is the very near term revenue this deal has brought to the table. 20% is a big deal on all the products that can be chucked straight into the retail shelf’s without the test phases. This is what is massive in the deal. Add that to a positive NXP001 trial with other news incoming and the next 4 to 8 weeks are going to be fascinating to watch. If these things come together which I feel that is exactly the plan and hence waiting to announce things like the major specialist broker then imo I feel the current MCAP will have a zero added to the end of it when this news is delivered. IMO!
 
Scaryone
Posts: 2,325
Opinion:Strong Buy
Price:3.18
RE: Look at the wording
22 Apr '19
I’d like to see a detailed timescale breakdown of the £51 million upfront payments..... also how long to market regarding caniboid products.
Looking good though
Aim4Utopia
Posts: 5,642
Premium Chat Member
Opinion:No Opinion
Price:3.18
Look at the wording
22 Apr '19
Near term- Strong Royalty’s . These are the key words imo

"Given the progress made with our NXP001 programme, we have proven our capability to develop products with a short path to market that utilise our IP and technology. The agreement allows Nuformix and its shareholders to benefit immediately from the upside of this attractive market without exposure to development and commercialisation risk. We are able to focus on developing our clinical and early-stage portfolios as planned, whilst generating significant near term revenue via attractive development milestones and a strong royalty component. We look forward to sharing further details with the market as the partnership progresses."




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk









Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.